Dr. Morgan's publications on Michigan Research Experts

Dr. Morgan's publications on PubMed

Select Publications

  1. Morgan, T.M., Lange, P.H., Porter, M.P., Lin, D.W., Ellis, W.J., Gallaher, I.H, Vessella, R.L.: Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res, 15:677-683, 2009. PMCID: PMC3162324.

  2. Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Morgan TM*, Tomlins SA* (co-senior): Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy Oncotarget, 8: 89848-6, 2017. PMCID: PM29163793

  3. Singhal, U, Wang, Y, Henderson, J, Niknafs, Y, Gursky, A, Zaslavsky, A, Smith, DC, Chang, L, Feng, FY, Palapatu, GS, Taichman, RS, Chinnaiyan, A, Tomlins, S, Morgan, TM: Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res, 16: 643-654, 2018.

  4. Morgan TM, Mehra R, Tiemeny P, Wolf JS, Wu S, Sangale Z, Brawer M, Stone S, Wu CL, Feldman AS: A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Years of Radical Nephrectomy for Renal Cell Carcinoma. Eur Urol, 73:763-9, 2018. PM29249291

  5. Morgan T.M., Meng M.V., Cooperberg M.R., Cowan J.E., Weinberg V., Carroll P.R., Lin D.W.: A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer and Prostatic Dis, 17: 174-179, 2014. PM24614692

  6. Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM: Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol, 34: 415, 2016. PMCID: PM27140065

  7. Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R: Prognostic value of percent Gleason grade 4 at prostate biopsy on predicting prostatectomy pathology and recurrence. J Urol 196: 405-11, 2016. PM26920466/26920466

  8. Hu, JC, Tosoian, JJ, Qi, J, Kaye, D, Johnson, A, Linsell, S, Montie, JE, Ghani, KR, Miller, DC, Wojno, K, Burks, F, Spratt, DE, Morgan, TM*: Clinical utility of gene expression classifiers in men with newly diagnosed prostate cancer. JCO PO, 2019

  9. Morgan, T.M., Barocas, D.A., Keegan, K.A., Cookson, M.S., Chang, S.S., Clark, P.E., Ni, S., Smith Jr., J.A., Penson, D.F.: Volume-outcomes in cystectomy: is it the surgeon or the setting? J Urol, 186: 2139-2144, 2012. PMID: 23083864.

  10. Morgan TM, Hawken SR, Ghani KR, Miller DC, Feng FY, Linsell SM, Salisz JA, Gao Y, Montie JE, Cher ML: Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy. Prostate Cancer Prostatic Dis, 19:216-21, 2016. PMCID: 26951715

  11. Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess R, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM: Independent Surgical Validation of the New Prostate Cancer Grade Grouping System. BJU Int: 2016. PM27009882

  12. Hawken SR, Spratt DE, Qi J, Linsell SM, Cher ML, Ghani KR, Miller DC, Montie JE, Morgan TM: Utilization of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy. Int J Radiat Oncol Biol Phys; 2019, (Epub ahead of print). PM30682490

  13. Qiao, Y, Feng, FY, Wang, Y, Cao, X, Han, S., Wilder-Romans, K, Keller, ET, Palapattu, GS, Taichman, RS, Alva, AS, Smith, DC, Tomlins, SA, Chinnaiyan, AM, Tomlins, SA, Morgan, TM: Mechanistic support for combined MET and AR blockade in castration resistant prostate cancer. Neoplasia, 18:1-9, 2016. PMCID: 26806347.

  14. Lee E, Decker AM, Cackowski FC, Kana LA, Yumoto K, Jung Y, Wang J, Buttitta L, Morgan TM, Taichman RS: Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptotic Pathway During Chemotherapy in Bone Marrow. J Cell Biochem 117 (12): 2815-2824, 2016. PM27153245

  15. Day KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, Shah R, Kunju LP, Hall C, Palanisamy N, Daignault-Newton S, El-Sawy L, Wilson SJ, Chou A, Ignatoski KM, Keller ET, Thomas DG, Nagrath S, Morgan TM, Day ML: HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res 77: 74-85, 2016. PMCID: PM27793843

  16. Patnaik A, Swanson KD, Csizmadia E, Solanki A, Elemento O, Novak J, Thornley TB, Morgan TM, Wang, Y, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC,: Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Anti-Tumor Innate Immunity. Cancer Discov, 8: 1158/2159-8290, 2017. PMCID: PM28274958